For Institutions
About
Macquarie's Tony Ren maintained a Buy rating on BeiGene Ltd with a price target of HK$236.00. The shares closed at HK$192.00. Ren, who covers the Healthcare sector, has an average return of 12.6% and a 58.70% success rate. BeiGene Ltd has a Strong Buy consensus with a price target of HK$239.97.
Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This patch is intended for analgesic and anti-inflammatory uses. The approval is a significant step in the company's R&D efforts. The most recent analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a HK$35.30 price target.
